Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial
Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial
复制标题
DOI：
10.1111/j.1525-1438.2006.00289.x
复制
发表时间：
2006-01-01
影响因子：
4.8
通讯作者：
Yaegashi, N
中科院分区：
文献类型：
--
作者：
Utsunomiya, H;Akahira, J;Yaegashi, N
紫杉醇（PTX）和铂（PLT）联合治疗卵巢透明细胞腺癌（CC）患者的治疗效果尚未阐明。在这项研究中，我们采用回顾性研究来评估PTX和PLT联合治疗可测量疾病的CC患者的结果。通过10家机构的病历资料，共鉴定出28例可测残留CC患者（原发15例，复发13例），经PTX-PLT联合化疗。采用实体瘤标准中的反应评价标准评价化疗的临床反应。在28例患者中，15例原发疾病患者中有8例（53.3%），13例复发疾病患者中有3例（23.1%）对PTX-PLT化疗有效。疾病晚期复发（12个月）的有效率为20%(1/5)，而早期复发（< 12个月）或难治性疾病的有效率为25%（2/8）。我们的研究结果表明，PTX和PLT联合使用可能比传统的不含PTX的基于PLT的化疗更有效。
The therapeutic effect of a combination of paclitaxel (PTX) and platinum (PLT) in ovarian clear cell adenocarcinoma (CC) patients with measurable disease has yet to be elucidated. In this study, we used retrospective review to evaluate the results of treatment with a combination of PTX and PLT in CC patients with measurable disease. A total of 28 patients with measurable residual CC (15 cases with primary disease, 13 cases with recurrent disease) treated with combination PTX-PLT chemotherapy was identified through medical records from ten institutions. Clinical response to chemotherapy was evaluated using Response Evaluation Criteria in Solid Tumors criteria. Of the 28 cases, 8 of 15 patients with primary disease (53.3%) and 3 of 13 patients with recurrent disease (23.1%) responded to PTX-PLT chemotherapy. The response rate for cases with late recurrent disease (> 12 months) was 20% (1/5), whereas the rate was 25% (2/8) for cases with early recurrent (< 12 months) or refractory disease. Our results indicate that the combination of PTX and PLT may have greater efficacy against CC than conventional PLT-based chemotherapy that does not include PTX.